28 results about "Heart contractility" patented technology

A system for application of neurostimulation includes an outer sheath, an elongate inner member in the outer sheath and movable relative to the outer sheath. The inner lumen has a distal end. An expandable member is coupled to the distal end of the inner member and is in the outer sheath. The expandable member is self-expanding upon from a compressed state in the outer sheath to an expanded state out of the outer sheath. The expandable member includes a distal portion including a plurality of wires woven together and a proximal portion including the plurality of wires extending parallel to a longitudinal axis. The system includes a plurality of electrode assemblies outward of the expandable member and circumferentially spaced around the expandable member. Each electrode assembly is coupled to two of the wires extending parallel to the longitudinal axis. Each electrode assembly includes a plurality of longitudinally-spaced electrodes.

Methods, apparatus, and systems are provided to control contraction of the heart. At least one sensing element receives signals indicating electrical activity of sinus rhythm of the heart. Based on the received signals, the progress of contraction of the heart is determined. Based on the progress of contraction, the chamber of the heart may then be stimulated at a plurality of locations. In another embodiment, a plurality of electrodes are implanted in the left ventricle to stimulate at multiple locations in the left ventricle for the purpose of improving hemodynamic performance and increasing cardiac output in a patient who is suffering from congestive heart failure.

1. A method for selecting a patient for cardiac contractile control therapy, the method comprising: selecting a patient who meets criteria for cardiac resynchronization therapy (CRT); detecting potential difficulties in effectively providing CRT to the patient; and determining that the patient can benefit from cardiac contractile control therapy despite the potential difficulties.

The disclosure relates to a method (100) for notifying a clotting event in an arterial line (1) of a human being (2), to a corresponding system, computer program product and data carrier signal. The method (100) comprises providing (110) a hemodynamic signal indicative of an arterial blood pressure waveform (10) in the arterial line (1); determining (120) a hemodynamic contraction parameter related to a contraction of the heart based on the hemodynamic signal; determining (130) a hemodynamic relaxation parameter related to a relaxation of the heart based on the hemodynamic signal; determining (140) a clotting event in the arterial line (1) in case the hemodynamic contraction parameter indicates a decrease of contractility and the hemodynamic relaxation parameter indicates an increase of contractility, and providing (150) a signal notifying of the determined clotting event.

This invention discloses an intraperitoneal balloon-assisted pacing implant kit, comprising: a guiding component, a dilation catheter component, and an inflation / deflation component. The guiding component includes a first guidewire, a portion of which is located inside the pericardial cavity of the target heart. The dilation catheter component includes a main tube and a balloon. The main tube has parallel guiding and air intake channels. The first guidewire is slidably connected within the guiding channels, guiding the main tube into the body. The balloon is positioned on the main tube and connected to the air intake channel. The main tube has a groove along its axial direction. Guided by the first guidewire, the balloon is embedded in the pericardial cavity of the target heart. Air is introduced through the air intake channel, causing the balloon to extend along the groove and surround the outside of the ventricle. The inflation / deflation component is connected to the balloon. With the support of ECG gating technology, the balloon expands during cardiac systole and contracts during diastole within the pericardial cavity, thereby compressing the left and right ventricles during cardiac systole.

The present invention provides an image processing device for evaluating cardiac images and a method for identifying ventricular states. In this method, regions of interest are identified from multiple target images, grayscale value changes of multiple pixels in the regions of interest in those target images are determined, and one or more representative images are obtained based on the grayscale value changes. The target images are pixels within the endocardial contour of the left ventricle, with the boundaries of the region of interest roughly located on both sides of the bottom of the endocardial contour, and the region of interest corresponds to the mitral valve. Grayscale value changes are related to the movement of the mitral valve. The representative images are used to evaluate the state of the left ventricle. In this way, the end-systole and end-diastole of the heart can be quickly and accurately identified.

A prosthetic heart valve has a frame and a valvular structure coupled thereto. The valvular structure has multiple leaflets, with paired tabs from the leaflets forming commissure tab assemblies that couple the valvular structure to the frame. The frame is tapered with its inflow end diameter being smaller than its outflow end diameter. The valvular structure is constructed such that a flow channel formed by the leaflets is also tapered, with the inlet end cross-section being smaller than the outlet end cross-section. The commissure tab assemblies are attached to the frame with leaflet bending axes at or adjacent to the radially-inner surface of the frame. During systole, separation of blood flow induced by the tapered geometry of the flow channel generates an annular back flow region adjacent to the inner surface of the valve at the outflow end, which prevents the free edge of the leaflets from contacting the frame.

The present invention discloses a component for in vitro near-physiological simulation of an isolated heart, belonging to the field of medical device technology. Its design purpose is to solve the many problems existing in existing in vitro heart simulation devices, simulate the physiological movement of the heart more accurately and simplify the valve movement observation process. The component includes a transparent shell, a top cover and a reciprocating pump. The shell has a accommodating chamber for placing the isolated heart, and the top cover has inflow and outflow channels respectively connected to the left atrioventricular orifice and the aortic orifice of the heart. An observation window is provided on the top cover to observe the valve movement. The reciprocating pump changes the hydraulic pressure of the accommodating chamber through an isolation membrane to cause the heart to contract and relax. The component is also provided with multiple pressure measuring interfaces and pressure measuring components, and the shell is polyhedron for easy observation. The component can be used to accurately simulate cardiac movement and is suitable for the evaluation of cardiac implantable medical devices, such as the evaluation of parameters such as the function, biomechanical properties and damage mechanism of interventional artificial valves, etc., providing a reliable in vitro simulation environment for the development and verification of medical devices.

Systems and methods for managing heart failure are described. The system receives physiological information including a first HS signal corresponding to paced ventricular contractions and a second HS signal corresponding to intrinsic ventricular contractions. The system detects worsening heart failure (WHF) using the received physiological information. A signal analyzer circuit can generate a paced HS metric from the first HS signal and a sensed HS metric from the second HS signal, and determine a concordance indicator between the paced and the sensed HS metrics. In response to the detected WHF, the system can use the concordance indicator to generate a therapy adjustment indicator for adjusting electrostimulation therapy, or a worsening cardiac contractility indicator indicating the detected WHF is attributed to degrading myocardial contractility.

A method of selecting a combination of electrodes for use in neurostimulation includes testing combinations of electrodes in an electrode array to identify an atrial capture. The atrial capture is indicated by at least one effect on an atrium. The method includes excluding electrodes with the atrial capture to result in remaining electrodes of the electrode array, testing combinations of the remaining electrodes of the electrode array for effect on cardiac contractility and / or relaxation, and selecting a combination of electrodes from the remaining electrodes. The selected combination has both a desired effect on cardiac contractility and / or relaxation and does not have an undesired side effect.

This invention relates to the fields of medical device technology and signal processing algorithm technology. Specifically, it relates to an in vitro cardiac contractility dynamic enhancement system and method based on R-wave peak dual-modal sensing. The problem addressed by this invention is the technical issues of poor safety, high oxygen consumption, insufficient precision, and lack of automated closed-loop control in isolated cardiac mechanical perfusion methods. To solve these problems, this invention provides an in vitro cardiac contractility dynamic enhancement method based on R-wave peak dual-modal sensing, comprising: obtaining an initial threshold and an initial R-wave template library based on real-time cardiac physiological signals within an initial target time period; obtaining the true R-wave peak based on waveform verification of candidate R-wave peaks within the target time period and the initial threshold; calculating the stimulation delay based on species-preset parameters and real-time cardiac physiological signals; and selecting the stimulation mode and adjusting the energy parameters based on changes in the real-time cardiac physiological signals.

This disclosure relates to a cardiac valve support device and a method for manufacturing and using the device. The device includes a flow optimizer configured to be located within the valve and having a cross-sectional area that reduces the reflux orifice of the valve during cardiac systole. The device includes an anchoring mechanism coupled to the flow optimizer and configured to fix the position of the flow optimizer relative to the valve. The flow optimizer allows for hemodynamic flow during diastole, minimizes the risk of inducing atrioventricular pressure gradients and thrombosis, and seals or minimizes the reflux orifice and restores valve efficacy during cardiac systole. The anchoring system does not require invasive interaction with the valve, atria, or ventricles. Implantation of the device can be achieved without invasive surgery. The device allows for intraoperative optimization of the positioning of the flow optimizer.

1. The name of the design product: sphygmomanometer (XB-12). 2. The use of the design product: monitoring the pressure value generated by blood to the blood vessel wall when the heart contracts and relaxes. 3. The design points of the design product: in the overall shape. 4. The picture or photo that best indicates the design points: perspective view.

A cardiac therapy device includes a stimulation circuit configured to generate a non-excitatory electrical signal that improves a condition of heart failure in a human patient when the non-excitatory electrical signal is applied to ventricular tissue during a ventricular refractory period of the ventricular tissue; an atrial arrhythmia detection circuit; and a decision circuit that controls the stimulation circuit to deliver the signal when the atrial arrhythmia detection circuit detects an atrial arrhythmia.

The invention relates to the technical field of biological medicines, in particular to application of indole-3-lactic acid in preparation of a medicine for treating heart failure. The application potential of indole-3-lactic acid (ILA) in treatment of ejection fraction retention type heart failure (HFpEF) is proposed and verified for the first time. By constructing a mouse HFpEF model, researches prove that ILA can significantly improve the diastolic function of the heart, specifically, the E / E'ratio is significantly reduced, and meanwhile, the left ventricular ejection fraction and the short-axis shortening rate are not affected, which indicates that the ILA effectively relieves the core pathological feature-diastolic dysfunction of the HFpEF on the basis of maintaining the systolic function of the heart.

The application provides a left ventricular implant and a left ventricular repair system. The left ventricular implant comprises a filling member arranged at a proximal end and a support member arranged at a distal end for supporting the filling member. The filling member comprises a filling body and a stent arranged in the filling body. When the heart contracts, the filling body and the stent are extruded, the stent is deformed, and the filling body is driven to move towards the proximal end. The unique stent structure cooperates to drive the filling body to move only towards the proximal end, and the movement direction is the same as the ejection direction, so that the proximal end of the filling body generates an additional force along the vertical axis direction to the blood flow ejected from the left ventricle to the aorta. While achieving the controlled movement direction of the proximal end of the filling body, the left ventricular pressure can be further increased. Therefore, the heart pumping function is enhanced, the physiological function of the diseased heart is improved, and sufficient blood flow is provided to meet the needs of the body.

The invention relates to the technical field of medical equipment, and discloses a wireless charging type cardiac contractility adjusting system which comprises an implantable control unit, a multi-channel electrode array, a wireless energy transmission system, a closed-loop feedback control module and an in-vitro program control terminal. The self-adaptive energy compensation system is arranged, when percutaneous wireless charging is carried out, tissue interface fluctuation in an energy transmission path is detected in real time, emission parameters are automatically adjusted through the dynamic tuning technology, it is guaranteed that the electromagnetic coupling efficiency is stable under different body positions, the charging interruption risk caused by respiratory movement can be eliminated, and the safety of percutaneous wireless charging is improved. A dynamic tracking system is arranged, when cardiac contractile force enhancement stimulation is carried out, ventricular repolarization characteristic signals are collected in real time, the dynamic offset of the effective refractory period of the myocardium is calculated, and a trigger window is dynamically adjusted after pace-making stimulation, so that the cardiac contractile force enhancement stimulation accurately falls into a safe period; and the arrhythmia triggering risk is reduced.

The invention relates to a self-adaptive control artificial heart valve testing device. The testing device comprises a pulsation generation module used for generating pulsation fluid simulating systole and diastole of the heart; the sensing feedback system is used for carrying out data acquisition on the pulsating fluid and feeding back the acquired fluid data to the control system; the control system is used for adaptively adjusting working state parameters of the pulsation generation module, the liquid volume execution unit and the liquid resistance execution unit according to the fluid data so as to realize pulsating flow in a near physiological state; and the valve loading module is used for installing a to-be-tested heart valve prosthesis, so that the heart valve prosthesis can be tested by utilizing pulsating fluid in a near-physiological state, and a testing device which can realize stable and continuous pulsating flow close to a real physiological state in vitro and has self-adaptive regulation and control capability is realized. The method is of great significance to simulation of pathological states of different patients, improvement of data consistency among laboratories and acceleration of research, development and manufacturing of artificial heart valves.

A prosthetic valve for treating blood regurgitation through a native heart valve can include a body including an inlet portion and an outlet portion having a first leaflet and a second leaflet, and the body defining a flow passage having an inlet within the inlet portion, a first outlet within the first leaflet, and a second outlet within the second leaflet; and a flow control device disposed in the flow passage within the inlet portion and a clip connector coupled to the body. The prosthetic valve is configured to be disposed in a native valve of a heart that has been pinched to create a first flow control portion and a second flow control portion, with the inlet disposed in a heart atrium and the first outlet and the second outlet disposed in a heart ventricle, wherein the leaflets are configured to be disposed in the flow control portions in substantially sealing relation with the first leaflet and the second leaflet. The prosthetic valve is further configured to allow blood to flow from the atrium to the ventricle through the flow passage and substantially prevent blood from flowing from the ventricle to the atrium through the flow passage or between the body and the leaflets during a contraction of the heart. The clip connector is configured to selectively couple to a clip and resist displacement of the body toward the atrium during the contraction.

The invention provides an integrated valved blood vessel construction and hemodynamic performance optimization method, the integrated valved blood vessel comprises a blood vessel pipeline and a valve, the valve comprises a plurality of valve leaflets, and the number of the valve leaflets is greater than or equal to four; a guide piece is arranged in the blood vessel pipeline, a guide groove is formed in the valve leaflet, and the guide piece is inserted into the guide groove and can slide in the guide groove; when the heart contracts, the side edges of every two adjacent valve leaflets can be far away from each other under the action of blood flow pressure, so that the valve is in an open state; when the heart is relaxed, under the action of the dead weight and the elasticity of the valve leaflets, the side edges of every two adjacent valve leaflets can be attached, and the valve is in a closed state. By increasing the number of the valve leaflets, the valve structure is firmer and can bear higher hydrodynamic load, so that the durability is improved; by arranging the guide piece and the guide groove, when the valve is opened and closed, the valve leaflet is forced to move along a preset track, the valve can be tightly closed after long-time use, and the service life of the valve is prolonged.

Methods and associated devices for enhancing peak VO2 in patients are disclosed.SOLUTION: A method of enhancing peak VO2, comprising: selecting a subject having an impaired peak VO2 and estimated to have a likelihood of improving peak VO2; and applying cardiac contractility modulation stimulation to the subject. The method includes detecting a ventricular contraction using one or more leads placed in a ventricle of the patient and applying a cardiac contractility modulating stimulus to the ventricle of the patient after a delay from a time of the detection.SELECTED DRAWING: Figure 1B

This application provides a self-expanding occlusion device for implantation between heart valves. The device includes a self-expanding body having: an elastic surface extending circumferentially along axis A to form a hollow cavity; a first port located proximal to the elastic surface and circumferentially surrounding axis A; and a second port located distal to the elastic surface and circumferentially surrounding axis A. The first port, the cavity, and the second port are interconnected. The second port is larger than the first port. This self-expanding occlusion device cleverly integrates its structure with the flow of blood during cardiac contraction and relaxation. For patients with valvular regurgitation, the self-expanding occlusion device can effectively resolve blood regurgitation in conjunction with the native valve during systole, and reduce obstruction of blood flow during diastole.

1. The name of the design product: sphygmomanometer (XB-11). 2. The use of the design product: monitoring the pressure value generated by blood to the blood vessel wall when the heart contracts and relaxes. 3. The design points of the design product: in the overall shape. 4. The picture or photo that best indicates the design points: perspective view.

The invention belongs to the technical field of medical instruments, and particularly relates to an ascending aorta covered stent with biomechanical property, which comprises a support skeleton, the inner side and the outer side of the support skeleton are both covered with films, the support skeleton is formed by spirally winding functional metal wires, the functional metal wires are formed by spirally winding composite wires, and the functional metal wires are wound by the composite wires. And the composite filament is formed by weaving a plurality of strands of filaments. In terms of overall performance, the large vessel covered stent can be highly synchronized with radial expansion / retraction, circumferential stretching, longitudinal displacement and slight torsion generated by the ascending aorta in the cardiac contraction and diastole period, and therefore natural physiological movement of the aorta is effectively simulated.

A system and method for assisting a heart in pumping blood, wherein the heart has external force requirements that need to be externally applied to the heart using a cardiac assist device that is powered by a drive fluid. The cardiac assist device is powered by a drive fluid having a pressure / flow profile that is customized to the needs of the heart. The pressure / flow profile is generated by a displacement pump. If the pressure / flow profile requires pressures that cannot be made by the displacement pump, then the pressure / flow profile can be altered by venting pressure and / or adding pressurized fluid into the system. In this manner, a precise pressure / flow profile can be produced that meets the exact needs of a heart being acted upon by a cardiac assist device.

Disclosed are methods and agents for treating heart failure. More particularly, the present disclosure relates to the use of CD14 antagonist antigen-binding molecules for treating heart failure, including alleviating, reducing or reversing adverse cardiac structural remodeling, improving cardiac contractile function, improving ejection fraction (e.g., left ventricular ejection fraction), left ventricular end-systolic volume, left ventricular end- diastolic volume, left ventricular akinesia, left ventricular dilatation, and / or left ventricular hypertrophy, reducing dyspnea, improving congestion score and / or patient perception of their health status and / or reducing neutrophil / lymphocyte ratio.

Methods and apparatus are provided for estimating a measure of cardiac contractility based on a set of features determined from a set of signals associated with a mechanical loop support device. The method includes determining, using a computer processor, a set of features based at least in part on the set of signals; providing the set of features as inputs to a machine learning model, the machine learning model trained to output a measure of cardiac contractility; and performing an action based at least in part on the measure of cardiac contractility output by the machine learning model.

To provide a therapy to patients with atrial fibrillation (AF), for example, to increase cardiac output, and to treat and / or prevent AF, AF symptoms, and / or other diseases.SOLUTION: A cardiac treatment device 200 includes: stimulation circuitry 204 configured to generate a non-excitatory electrical signal which, when applied to ventricular tissue during a ventricular refractory period thereof, improves a condition of heart failure in human patients; atrial arrhythmia detection circuitry 208; and decision circuitry 202 which controls the stimulation circuitry 204 to deliver the signal also when the atrial arrhythmia detection circuitry 208 detects an atrial arrhythmia.SELECTED DRAWING: Figure 2